ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Diagnostic Oncology

Optimal Pathologic Staging of Lung Cancer Depends on More Than the Pathologist

Mary Beth Beasley, MD
on: April 26, 2022In: Diagnostic Oncology
Optimal Pathologic Staging of Lung Cancer Depends on More Than the Pathologist

Pathology—and pathologic staging in particular—can be improved through multidisciplinary efforts. Read more


Low-Dose CT, ctDNA May Partner for Lung Cancer Detection

Leah Lawrence
on: March 23, 2022In: Diagnostic Oncology, Meeting News, Screening/ED
Low-Dose CT, ctDNA May Partner for Lung Cancer Detection

Liquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT. Read more

Award Lecture Highlights Tumor Evolution Through Liquid Biopsy

Leah Lawrence
on: March 23, 2022In: Diagnostic Oncology, Meeting News
Award Lecture Highlights Tumor Evolution Through Liquid Biopsy

The UK’s Dr. Charles Swanton received the ISLB’s 2021 award for outstanding scientific contribution. Read more

Enhancing Understanding of Testing Applications, Best Practices: A Q&A with Dr. Lynette M. Sholl

Lynette M. Sholl, MD
on: January 26, 2022In: Diagnostic Oncology
Enhancing Understanding of Testing Applications, Best Practices: A Q&A with Dr. Lynette M. Sholl

Lynette M. Sholl, MD, Chief of Thoracic Pathology and Associate Director of the Center for Advanced Molecular Diagnostics at Brigham and Women’s Hospital and Associate Professor at Harvard Medical School, […] Read more

IASLC GENERAL DISCLAIMER

on: February 05, 2021In: Diagnostic Oncology
IASLC GENERAL DISCLAIMER

All information and materials presented on or through IASLC’s websites, or made available or provided by or on behalf of IASLC during any webinar, seminar, or other event or activity, […] Read more

Multidisciplinary EURACAN/IASLC Proposal for Revision of the Histologic Classification of Malignant Pleural Mesothelioma 

Sanja Dacic
+more
on: January 20, 2021In: Diagnostic Oncology
Multidisciplinary EURACAN/IASLC Proposal for Revision of the Histologic Classification of Malignant
            Pleural Mesothelioma 

Sponsored by EURACAN and the IASLC, a multidisciplinary group comprised of pathologists, oncologists, surgeons, radiologists, and molecular biologists met July 5 and 6, 2018, to critically review the current histologic […] Read more

Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey 

Matthew P. Smeltzer, PhD
+more
on: January 13, 2021In: Behind the Scenes, Diagnostic Oncology, WCLC 2020 Archive
Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey 

The past 10 years have seen a dramatic increase in novel therapeutic options for patients with lung cancer, with many treatments now personalized to the specific tumor characteristics of each […] Read more

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapies

Sanja Dacic
+more
on: September 29, 2020In: Diagnostic Oncology, Evolving Standards of Care
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens
            Following Neoadjuvant Therapies

Treatment guidelines recommend neoadjuvant or adjuvant therapies with surgery for patients with large primary tumors or clinical evidence of intrathoracic nodal spread.1,2 A recent joint IASLC–U.S. Food and Drug Administration […] Read more

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

on: April 15, 2020In: Diagnostic Oncology
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more

Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

on: February 12, 2020In: Diagnostic Oncology
Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients […] Read more

12
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy